LGT Group Foundation Takes Position in Illumina, Inc. (NASDAQ:ILMN)

LGT Group Foundation purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 17,358 shares of the life sciences company’s stock, valued at approximately $2,320,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bleakley Financial Group LLC acquired a new position in shares of Illumina in the 4th quarter valued at $751,000. Zacks Investment Management acquired a new position in shares of Illumina in the 3rd quarter valued at $2,924,000. Van ECK Associates Corp grew its holdings in shares of Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after buying an additional 22,718 shares during the period. Strategic Financial Concepts LLC acquired a new position in shares of Illumina in the 4th quarter valued at $1,464,000. Finally, Allworth Financial LP grew its holdings in shares of Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after buying an additional 6,263 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ILMN. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and cut their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $130.00 to $100.00 in a research report on Monday, February 10th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a research report on Friday. Finally, Royal Bank of Canada cut their price objective on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $155.45.

Illumina Stock Down 5.1 %

Shares of ILMN stock opened at $84.20 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm’s 50-day moving average is $122.36 and its 200-day moving average is $132.81. The stock has a market cap of $13.34 billion, a price-to-earnings ratio of -10.96, a PEG ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 52-week low of $83.79 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.